DBV Technologies
$ 18.23
-3.03%
02 Jun - close price
- Market Cap 1,112,705,000 USD
- Current Price $ 18.23
- High / Low $ 18.33 / 17.40
- Stock P/E N/A
- Book Value 3.52
- EPS -4.50
- Next Earning Report 2026-07-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.66 %
- ROE -1.59 %
- 52 Week High 26.18
- 52 Week Low 7.94
About
DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, France.
Analyst Target Price
$40.66
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-03-27 | 2025-10-28 | 2025-07-29 | 2025-04-30 | 2025-03-27 | 2024-11-06 | 2024-07-30 | 2024-05-07 | 2024-03-07 | 2023-10-31 | 2023-07-31 |
| Reported EPS | -0.09 | -0.1994 | -0.21 | -0.27 | -0.23 | -0.2126 | -1.49 | -1.57 | -5.2 | -0.0581 | -1.61 | -2.36 |
| Estimated EPS | -0.17 | -0.1886 | -0.29 | -0.16 | -0.22 | -0.21 | -1.64 | -2.65 | -2.06 | -0.23 | -2.63 | -2.27 |
| Surprise | 0.08 | -0.0108 | 0.08 | -0.11 | -0.01 | -0.0026 | 0.15 | 1.08 | -3.14 | 0.1719 | 1.02 | -0.09 |
| Surprise Percentage | 47.0588% | -5.7264% | 27.5862% | -68.75% | -4.5455% | -1.2381% | 9.1463% | 40.7547% | -152.4272% | 74.7391% | 38.7833% | -3.9648% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-29 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.09 |
| Currency | EUR |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DBVT
2026-06-02 10:39:52
DBV Technologies' stock fell midday, breaking a key support level ahead of its mixed general assembly. The French biotech company is experiencing a short-term negative dynamic, with its stock trading below its MM20 and MM50, and a significant increase in short positions. However, its annual performance remains positive, and the stock is still above its MM200.
2026-06-01 13:08:00
DBV Technologies stock fell nearly 4% at midday, making it one of the steepest declines in the SBF 120, despite the broader index's slight gain. The stock is approaching a critical support level of €3.19 and has dropped significantly below its short-term moving averages. This comes amidst increasing short interest from institutional investors and ahead of a mixed general meeting, with the company still anticipating key FDA filings for its Viaskin Peanut patch in 2026.
2026-05-30 06:39:45
DBV Technologies (ENXTPA:DBV) has seen recent stock movement, closing at €3.36, and while its one-year return is strong, the 30-day return is down. The company is currently loss-making but analysts expect profitability within three years, with a target price of €3.80. Valuation signals are mixed, with a Price-to-Book ratio of 5.6x suggesting overvaluation compared to peers, but a Discounted Cash Flow model indicates the stock is deeply undervalued at €3.36 against an estimated fair value of €70.56.
2026-05-26 11:35:00
DBV Technologies stock has declined by 16% over the last three months, trading at €3.22, and is approaching a key support level at €3.19. Despite this recent downturn and dropping below its short-term moving averages, the stock's annual performance remains significantly positive at +117.2%. The French biotech company maintains solid cash reserves until Q2 2027 and plans two major FDA filings in 2026 for its Viaskin Peanut allergen patch.
2026-05-25 09:37:00
J.P. Morgan Chase & Co. has reported to the AMF that its indirect holding in DBV Technologies has fallen below the 10% threshold for capital and voting rights as of May 19. The banking group now holds 26,316,127 DBV shares, representing 8.89% of the company's capital and voting rights, following a reduction in shares held through assimilation. DBV Technologies specializes in diagnostic and treatment solutions for food allergies.
2026-05-23 07:09:17
This article announces that DBVT is scheduled to report its financial results on April 30. Investors will be keen to see if the company's performance has deviated from consensus estimates. The report will provide insights into DBVT's financial health and future outlook.
